Fleischmann, R., Friedman, A., Drescher, E., Singhal, A., Cortes-Maisonet, G., Doan, T., Lu, W., Wang, Z., Nader, A., Housley, W., Cohen, S., Taylor, P. C., & Blanco, R. (2022). safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. Lancet, 4, e395–e406. http://access.bl.uk/ark:/81055/vdc_100155168771.0x000001